Few pharmacological treatments for alcohol dependence are available. Moreover, the best supported treatment, naltrexone hydrochloride, appears to work for only some.
To investigate potential predictors of these differential responses, 40 social drinkers (20 women) were administered 6 days of treatment with naltrexone vs. placebo in a double-blind, counterbalanced, crossover design. At the end of each treatment period, participants received a single dose of their preferred alcoholic beverage followed by the opportunity to work for additional alcohol units using a progressive ratio (PR) breakpoint paradigm. All subjects but one were genotyped for the A118G polymorphism of the mu opioid receptor gene (OPRM1).
Naltrexone decreased the ethanol-induced ‘euphoria’ to a priming dose of alcohol in two subgroups: (i) in women, and (ii) in subjects with the A118G polymorphism of the mu opioid receptor gene (OPRM1).
Naltrexone did not decrease motivation to work for additional alcoholic beverages on the PR task regardless of gender or genotype.
Naltrexone did not decrease motivation to work for additional alcoholic beverages on the PR task regardless of gender or genotype.
The results add to the evidence that naltrexone decreases positive subjective effects of alcohol, with preferential effects in distinct subgroups. Similar effects in heavier drinkers might decrease alcohol use.
Read Full Abstract
Request Reprint E-Mail: marco.leyton@mcgill.ca
Read Full Abstract
Request Reprint E-Mail: marco.leyton@mcgill.ca
